(Informaci\u00f3n remitida por la empresa firmante)<\/p>\n
\nBARCELONA, Spain, May 28, 2024 \/PRNewswire\/ — Sanofi is all in on AI and wants to become the first biopharma company powered by AI at scale. The company is using AI to chase the miracles of science by accelerating drug discovery, enhancing clinical trial design and improving the manufacturing and supply of medicines and vaccines to get them to patients in need faster. Bluecrux’s digital supply chain twin technology, Axon, plays a critical role in Sanofi’s digital supply chain transformation.<\/p>\n
Delivering miracles of science to patients<\/p>\n
\nThe company is paving the way as a leader in innovation among pharma companies with its broad AI implementation, enhancing operational capabilities across various domains of the business. Sanofi’s ambition is particularly pronounced in its supply chain strategy, in which AI is pivotal in \u00abdelivering miracles of science to patients.\u00bb With greater efficiency, the company can redirect savings toward R&D and medicine development.<\/p>\n
Bluecrux’s Axon plays a critical role in Sanofi’s digital supply chain transformation. Axon is a digital twin that integrates and harmonizes all Sanofi’s data systems into ONE single digital value chain model. This allows for a comprehensive understanding of Sanofi’s supply chain operations from start to finish. \u00abThe end-to-end visibility of our supply chain value stream has already helped us identifying large opportunities to improve inventory and process cycle times that will ultimately get our products to patients faster\u00bb, says Leif Skibsted Jakobsen, Head of Digital Supply Chain Sanofi. \u00abWe have put in place a structured process for implementing these opportunities and with Axon we are also able to validate the results.\u00bb <\/p>\n
\u00abAxon is an important puzzle piece in supporting Sanofi’s aims to create an E2E-connected, data driven and digitally accelerated supply chain\u00bb, adds Valerie Vandenbroucke, VP for Axon Technology Bluecrux. \u00abAlthough the use of the platform is already transformational, the journey has just begun, with many more breakthroughs on the horizon.\u00bb <\/p>\n
\nSanofi and Bluecrux at Gartner Barcelona<\/p>\n
\nAt the upcoming Gartner Supply Chain Symposium EMEA conference in Barcelona (June 10-12), Bluecrux will join Sanofi in a special session that will delve into the transformative power of artificial intelligence in the realm of supply chain management. Val\u00e9rie Vandenbroucke, VP of Bluecrux’s Axon Technology, and Sanofi’s Leif Skibsted Jakobsen will be co-presenting.<\/p>\n
During the session, attendees will gain insights into how Sanofi has harnessed AI to meet and exceed its business objectives. It will explore how Sanofi translated its vision into a practical roadmap and how AI can catalyze a true transformation in supply chain management, including helping the company become an E2E-connected, data-driven and digitally accelerated supply chain.<\/p>\n
About Sanofi<\/p>\n
\nWe are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.<\/p>\n
\nSanofi is listed on EURONEXT: SAN and NASDAQ: SNY<\/p>\n
\nAbout Bluecrux<\/p>\n
\nFounded in 2011, Bluecrux is a leading value chain technology and consulting company, assisting global companies to navigate and improve their supply chains. The company’s global reach and innovative technologies, Binocs and Axon, reflect its goal to combine expertise with technology, turning challenges into opportunities.<\/p>\n
View original content:https:\/\/www.prnewswire.co.uk\/news-releases\/bluecrux-supports-sanofi-in-harnessing-ai-to-transform-supply-chains-for-tomorrow-302156155.html<\/p>\n","protected":false},"excerpt":{"rendered":"
(Informaci\u00f3n remitida por la empresa firmante) BARCELONA, Spain, May 28, 2024 \/PRNewswire\/ — Sanofi is all in on AI and wants to become the first biopharma company powered by AI at scale. The company is using AI to chase the miracles of science by accelerating drug discovery, enhancing clinical trial design and improving the manufacturing […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[],"class_list":["post-52982","post","type-post","status-publish","format-standard","hentry","category-noticias"],"_links":{"self":[{"href":"https:\/\/webciudadana.net\/index.php?rest_route=\/wp\/v2\/posts\/52982","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/webciudadana.net\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/webciudadana.net\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/webciudadana.net\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/webciudadana.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=52982"}],"version-history":[{"count":0,"href":"https:\/\/webciudadana.net\/index.php?rest_route=\/wp\/v2\/posts\/52982\/revisions"}],"wp:attachment":[{"href":"https:\/\/webciudadana.net\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=52982"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/webciudadana.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=52982"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/webciudadana.net\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=52982"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}